Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Chunhong Hu et al.|The Lancet Oncology|2011Cited by 4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C. Zhou, Changxuan You, Yi‐Long Wu et al.|Annals of Oncology|2015Cited by 467
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G. Chen, Changxuan You, J. Feng et al.|Annals of Oncology|2013Cited by 120
A network pharmacology-based study on the anti-hepatoma effect of Radix Salviae MiltiorrhizaeYi Luo, Ming Hong|Chinese Medicine|2019Cited by 43
Lactylation orchestrates ubiquitin-independent degradation of cGAS and promotes tumor growthKeqiang Rao, Jing He, Xinchao Zhang et al.|Cell Reports|2025Cited by 34